Bregantini D, Schmitt LHM, Thijssen JJJ. A Bayesian change-point detection approach to the economic evaluation of risky projects: an application to healthcare technology assessment. J R Stat Soc Ser A Stat Soc. 2023 Nov 22. doi: 10.1093/jrsssa/qnad129
Bhatia S, Nghiem P, Veeranki SP, Vanegas A, Lachance K, Tachiki L, Chiu K, Boller E, Bharmal M. Real-world clinical outcomes with avelumab in patients with Merkel cell carcinoma treated in the USA: a multicenter chart review study. J Immunother Cancer. 2022 Aug;10(8):e004904. doi: 10.1136/jitc-2022-004904
Bhatia S, Nghiem P, Veeranki SP, Vanegas A, Lachance K, Tachiki L, Chiu K, Boller E, Bharmal M. Real-world clinical outcomes among patients with advanced Merkel cell carcinoma treated with avelumab in academic medical centers in the United States. Poster presented at the SITC 2021 36th Anniversary Annual Meeting; November 9, 2021. Washington, DC. [abstract] J Immunother Cancer. 2021 Nov; 9(Suppl 2):A658.
Rothman KJ, Hatch EE, Poole C, Wise LA, Gallacher JEJ, Lash TL, Mikkelsen EM, Sorensen HT. Comment on "Perils and Potentials of Self-Selected Entry to Epidemiological Studies and Surveys". J R Stat Soc Ser A Stat Soc. 2016 Feb;179(2):364. doi: 10.1111/rssa.12136
Brown TM, Horblyuk RV, Grotzinger KM, Matzdorff AC, Pashos CL. Patient-reported treatment burden of chronic immune thrombocytopenia therapies. BMC Blood Disord. 2012 Mar 1;12(1):2.